| Valuation method | Value, € | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 89.70 | -43 |
| Intrinsic value (DCF) | 137.79 | -12 |
| Graham-Dodd Method | n/a | |
| Graham Formula | 99.60 | -37 |
AstraZeneca PLC (ZEG.DE) is a leading global biopharmaceutical company headquartered in Cambridge, United Kingdom, specializing in the discovery, development, manufacturing, and commercialization of prescription medicines. The company operates across multiple therapeutic areas, including oncology, cardiovascular, renal, and metabolism diseases, respiratory and immunology, rare diseases, and infectious diseases. AstraZeneca's robust product portfolio includes blockbuster drugs such as Tagrisso, Lynparza, and Farxiga, alongside COVID-19 vaccines like Vaxzevria. With a strong presence in the UK, Europe, the Americas, Asia, Africa, and Australasia, AstraZeneca serves primary and specialty care physicians through a network of distributors and local offices. The company actively engages in strategic collaborations, such as partnerships with Regeneron Pharmaceuticals and Ionis Pharmaceuticals, to advance innovative treatments. AstraZeneca's commitment to R&D and its diversified pipeline position it as a key player in the global pharmaceutical industry, addressing critical unmet medical needs.
AstraZeneca presents a compelling investment opportunity due to its diversified and high-growth product portfolio, strong R&D pipeline, and strategic collaborations. The company's revenue of €54.07 billion and net income of €7.04 billion in the latest fiscal year underscore its financial stability. With a market capitalization of approximately €192.82 billion and a low beta of 0.176, AstraZeneca offers defensive characteristics suitable for risk-averse investors. The company's operating cash flow of €11.86 billion supports its dividend payout of €2.92 per share, appealing to income-focused investors. However, risks include high total debt of €30.11 billion and competitive pressures in the pharmaceutical sector. AstraZeneca's focus on innovation and expansion in emerging markets mitigates some of these risks, making it an attractive long-term investment.
AstraZeneca holds a competitive edge in the pharmaceutical industry through its strong R&D capabilities, diversified therapeutic portfolio, and strategic partnerships. The company's oncology segment, featuring drugs like Tagrisso and Lynparza, competes effectively with rivals such as Roche and Merck & Co. In cardiovascular and metabolic diseases, Farxiga's strong performance positions AstraZeneca favorably against competitors like Novo Nordisk and Eli Lilly. The company's respiratory portfolio, including Symbicort and Fasenra, faces competition from GSK and Sanofi. AstraZeneca's COVID-19 vaccine, Vaxzevria, though less dominant than Pfizer-BioNTech's offering, contributed significantly during the pandemic. The company's collaborations with biotech firms enhance its pipeline, ensuring long-term growth. However, AstraZeneca's reliance on a few blockbuster drugs exposes it to patent cliffs and generic competition. Its extensive global footprint and focus on emerging markets provide a buffer against regional economic fluctuations, reinforcing its competitive positioning.